

May 18

Consensus program organized by IMSCOGS Steering Committee

Coordinator: Menno Schoonheim

9:15: General opening

9:30: Fatigue and cognition in MS

Chairs: Lauren Krupp (NY), Aurélie Ruet (Bordeaux)

09:30: Fatigue in MS: Only a physical problem? (*Lauren Krupp, NY*)

09:45: Cognitive fatigue in MS: What is it and how do we measure it? (*Sarah Morrow, London, ON*)

10:00: COVID-19: Impact on cognition or is it all fatigue? (*Maria Petracca, Naples*)

10:15-10:30: Break

10:30: Mechanisms of fatigue: Distinct from cognition? (*Zina-Mary Manjaly, Zürich*)

10:45: How do we treat fatigue and how does this impact cognition? (*Letizia Leocani, Milan*)

11:00: General discussion

11:15: Free communications 1

Chairs: Iris K Penner (Bern)

O1: Feasibility of detecting atrophy relevant for cognition on 3D-FLAIR


S. Noteboom, M.D. Steenwijk, D.R. van Nderpelt, E.M.M. Strijbis, B. Moraal, M.W.A. Caan, F. Barkhof, H.Vrenken, M.M. Schoonheim (Amsterdam).

O2: Brain age as a surrogate marker for IPS in MS

S Denissen, DA Engemann, A De Cock, L Costers, J Baijot, J Laton, IK Penner, M Grothe, M Kirsch, MB D'hooghe, M D'haeseleer, D Dive, J De Mey, J Van Schependom, D Sima, G Nagels. (Brussels).

O3: Altered diffusion in lesional and normal-appearing cortex is related to cognitive impairment in multiple sclerosis

Krijnen EA, Bajrami A, Broeders TAA, Koubiyr I, Bouman PM, Steenwijk M, Klawiter EC Schoonheim MM (Amsterdam).

11:45-12:45: Industry symposium :  Bristol Myers Squibb™

12:45-14:00: Lunch

14:00: Atrophy and cognition in MS

Chairs: Celine Louapre (Paris), Menno Schoonheim (Amsterdam)

14:00: Pathological substrates of atrophy, related to cognition?

(Roberta Magliozzi, Verona)

14:15: Are global atrophy measures good enough for cognition?

(Maria Pia Sormani, Genova)

14:30-14:45: Break

14:45: Which regions are important to monitor for atrophy in

MS: Disability versus cognition? *(Niels Bergsland, Buffalo)*

15:00: How are cognitively relevant atrophy patterns related to connectivity and networks? *(Paolo Precioza, Milan)*

15:15: General discussion

15:30: Debate

Is clinic ready to implement fatigue and atrophy to identify patients at risk for CI *(all speakers)*

16:15: Free communications 2

Chairs: Mathilde Deloire, Bruno Brochet (Bordeaux)

O4: Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis

Román, CAF, Wylie, GR, DeLuca, J, & Yao, B (West-Orange).

O5: Multilingualism as a protective factor against cognitive impairment in multiple sclerosis

A Balusha, H Rosehart, C Casserly, J Racosta, SA. Morrow (London, ON).

16:35-16:55: Break

16:55: General assembly *(members)*

19:30: Opening Gala *(see details on page 10)*

May 19

Annual IMSCOGS MEETING Organized by IMSCOGS EXECUTIVE BOARD

Coordinator: Bruno Brochet

8:30: New clinical perspectives

Chairs: Maria-Pia Amato (Florence), Pierre Clavelou (Clermont-Ferrand)

Cognitive assessment

08:30: Cognition and relapses in MS (*Ralph H Benedict, Buffalo*)

08:45: Cognitive profiles in MS (*Ermelinda De Meo, Florence*)

The impact of cognitive impairment

09:00: Driving (*Sarah Morrow, London*)

09:15: Familial and social relationships (*Helen Genova, West Orange*)

09:30: General discussion

9:45: What does new imaging techniques could bring to the study of cognitive disorders in MS?

Chairs: Bruno Brochet (Bordeaux), Thomas Tourdias (Bordeaux)

09:45: The cortex at 7T (*Céline Louapre, Paris*)

10:00: Multi-TE and Dynamic ²³Na MRI (*Jean-Philippe Ranjeva, Marseille*)

10:15: Social cognition networks in MS (*Aurélie Ruet, Bordeaux*)

10:30: General discussion

10:40-11:00: Break

11:00: Free communications 3

Chairs: Jean-Christophe Ouallet (Bordeaux)

O6: A Taxonomy of Cognitive Phenotypes in MS

L Hancock, B Hermann (Madison).

O7: Cognitive performance is related to GABA-receptor density in multiple sclerosis

M Huiskamp, M Yaqub, MR van Lingen, PJ. Pouwels, LR. de Ruiten, BN. van Berckel, R Boellaard, SS. Golla, JJ. Geurts, HE. Hulst (Amsterdam).

11:20: New perspectives: Cognition and motricity

Chairs: Bruno Stankoff (Paris), Delphine Lamarque (Bordeaux)

11:30: Physical activity and cognition in MS (*Brian Sandroff, West Orange*)

11:35: Motor-Cognition interferences (*Peter Feys, Hasselt*)

11:55: Discussion

12:00-12:30: Industry symposium



12:30-13:45: Lunch

13:45: Longitudinal perspective in imaging

Chairs: Ismail Koubiyr (Bordeaux), Olivier Heinzlef (Poissy)

13:45: Cognition as a marker of progression (*Iris K Penner, Bern*)

14:00: Longitudinal study of brain abnormalities and connectivity in early MS (*Ismail Koubiyr, Bordeaux*)

14:15: Longitudinal study of dynamic functional network connectivity in CIS (*Paola Valsasina, Mara Rocca, Milan*)

14:30: Long-term course and morphological MRI correlates of cognitive function in MS (*Stefanie Hechenberger, Graz*)

14:45: The sequence of structural, functional, and cognitive changes in MS (*Menno Schoonheim, Amsterdam*)

15:00: General discussion

15:15: Free communications 4

Chairs: Gilles Defer (Caen)

O8: Distribution of cortical lesions across functional networks is non-random and related to cognitive impairment

Bajrami A, Krijnen EA, Koubiyr I, Bouman PM, Steenwijk MD, Klawiter EC, Calabrese M, Schoonheim MM (Amsterdam).

O9: Cognitive decline in early RRMS is linked to altered sodium MRI in functional brain networks

D Jandric, D Lewis, D McHugh, L Parkes, H Haroon, D Rog, D Paling, GJM Parker, N Muhlert (Manchester).

15:35-15:50: Break

15:50: Therapy

Chairs: Friedemann Paul (Berlin), Ralph Benedict (Buffalo)

15:50: MS patients' understanding of treatment risks and benefits in clinical consultations (*Dawn Langdon, London*)

16:05: DMTs and cognition in MS: escalation or induction strategy? (*John DeLuca, West Orange*)

16:20: Cannabinoids and cognition in MS: what should we advise? (*Anthony Feinstein, Toronto*)

16:35: How to improve cognition in Pediatric MS? (*Lauren Krupp, NY*)

16:50: Cognitive Rehabilitation in MS: Which strategy for memory impairment? (*John DeLuca, West Orange*)

17:05: Cognitive Rehabilitation in MS: Which strategy for IPS impairment?

(*Bruno Brochet, Bordeaux*)

17:20: General discussion

17:30: End